far too early to tell, but autoimmune is a new area for IMGN and a very large market. Looking forward to hearing about preclinical testing results and plans for clinical development. On the + side, autoimmune trials do not take years to complete. On the - side competition is stiff and side effects are less tolerable for most autoimmune indications compared to onclolgy. If early results are good, many companies will want to partner and in 1-2 years, this could become a primary value driver. They will need to hire some people with a different skill set, but have VRTX in the area from which to draw.